Boston Scientific Climbs 2% After Steep Decline, Regains 38% of Thursday’s Loss

NEW YORK, August 21, 2026, 16:45 EDT — U.S. markets have ended trading for the day.

• Boston Scientific finished at $50.37, gaining 2.03%, with 31.8 million shares traded.
• Friday’s rebound recouped just 38% of Thursday’s decline; the stock finished the week down 2.82%.
• Analysts continue to forecast an average upside of 24.46%, though five out of 31 now assign a Hold rating to the shares.

Boston Scientific Corporation NYSE:BSX gained 2.03% on Friday, recovering under 40% of Thursday’s decline. Shares settled at $50.37 at 16:00:02 EDT. Trading volume was 31.76 million, surpassing the three-month average by 51.8%.

The mix is significant. High turnover was seen during a partial rebound, rather than a complete recovery. Boston Scientific ended 2.82% lower compared to its August 14 close.

Friday saw a broad trading range, with the stock climbing as much as 3.41% from its $49.22 opening price before ending the session 1.04% down from the day’s $50.90 peak. The closing value increased equity by approximately $1.45 billion, according to the stated $73.0 billion market capitalization.

The underlying fundamentals show more strength than share performance suggests. Sales for the second quarter increased 7.5% to $5.442 billion. Adjusted earnings were $0.86 per share, exceeding the company’s guidance range of $0.82 to $0.84.

Chief Executive Mike Mahoney said, “Our team delivered a solid quarter while continuing to navigate a dynamic environment.” The company also carried out a $2 billion accelerated buyback, retiring roughly 40 million shares. Company statement

However, management lowered its adjusted EPS guidance for the full year to a range of $3.28–$3.32. The company is facing weaker WATCHMAN demand along with increased competition in U.S. electrophysiology, impacting performance for the rest of the year.

Wall Street sentiment stays positive. S&P Global data collected by StockAnalysis indicate that 26 out of 31 analysts rated the stock as Buy or Strong Buy in August. This compares to 34 out of 34 in those categories back in March.

Jefferies analyst Matthew Taylor maintained a Buy rating on Friday, setting a price target at $60. The consensus target stands at $62.69, which suggests an upside of 24.46%. The median target is $60, with forecasts ranging from $44 to $94.

Boston Scientific’s planned $14.5 billion takeover of Penumbra NYSE:PEN increases pressure on execution. The company projects adjusted EPS dilution of $0.06–$0.08 for the initial full year post-deal, then expects the transaction to be neutral or modestly accretive by the second year.

The upcoming test next week is simple. As U.S. markets reopen on Monday, investors will look to see if trading volumes above the norm can maintain the shares above $50. Any news regarding Penumbra’s financing or regulatory approvals will be more significant than a single-day rally.

Risks: A slower performance from WATCHMAN, increased competition in U.S. electrophysiology, and dilution from acquisitions may hold back a rerating. Conversely, a stronger pace of product adoption or smoother execution by Penumbra might lift the shares more quickly than anticipated.

Boston Scientific’s upcoming earnings announcement is set for October 28. Until that release, investors continue to focus on the contrast between the company’s steady operating growth and its shares having fallen over the past 52 weeks.

Related articles: NYSE:BSX

▶

29 July 2026

Boston Scientific (NYSE:BSX) shares fall as international growth offsets slower U.S. cardiac performance